Dr Cohen on the Efficacy of Pirtobrutinib in High-Risk Patients With MCL

Jonathon B. Cohen, MD, MS, discusses safety and efficacy outcomes with pirtobrutinib in previously treated patients with relapsed/refractory mantle cell lymphoma, as observed in the phase 1/2 BRUIN study.

Related Keywords

Jonathonb Cohen , ,Emory University School Of Medicine ,Winship Cancer Institute ,Safety Monitoring Committee ,Department Of Hematology ,Lymphoma Program ,Medical Oncology ,Emory University School ,Ash Annual Meeting ,Onclive Tv ,Conference ,Mantle Cell Lymphoma ,Cmcl ,